Cepheid’s molecular test determines ER/PR/HER2/Ki-67 with less variable results compared to IHC/FISH

Please log in for more information

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Visit www.cepheid.com/en to view our entire portfolio of molecular diagnostic tests and systems.

1. CE-IVD. In Vitro Medical Device. Not available in all countries. Not available in the United States.
2. Xpert® Breast Cancer STRAT4 Package Insert. Sunnyvale. USA. 2017

Contact Information:

Cepheid | Vira Solelh | 81470 Maurens-Scopont, France
PHONE +33.563.82.53.00
FAX +33.563.82.53.01

Company website

About Cepheid's Oncology Tests

Cepheid’s innovative oncology program offers a growing menu of molecular diagnostic tests that currently focuses on cancers of the breast, bladder, and blood. Leveraging Cepheid’s proven molecular diagnostics platform, our oncology products deliver on-site, on-demand, accurate, and reliable results. The pioneering mindset of our team is bolstered by Cepheid’s strong molecular biology capabilities, extensive global infrastructure, and an unwavering commitment to scientific rigor. Our vision is to deliver life-changing technology to physicians and their cancer patients globally.

Subspecialties Oncology

I’m Methylation Man

02/23/2024 | Sponsored by Illumina